首页> 外文期刊>Advances in Experimental Medicine and Biology >Separation of Factor V Leiden molecule, a mutated form of Factor V, from plasma of homozygous patient.
【24h】

Separation of Factor V Leiden molecule, a mutated form of Factor V, from plasma of homozygous patient.

机译:从纯合患者血浆中分离出因子V的突变形式的因子V Leiden分子。

获取原文
获取原文并翻译 | 示例
       

摘要

Factor V (FV) is a coagulant in plasma. The FV molecule consists of a heavy chain and a light chain, and Factor V Leiden (FVL) is mutated FV at a single amino acid in the heavy chain. FVL patients are in a dangerous hyper-coagulation state in their body. Current FVL diagnosis is done by DNA analysis, which is expensive and time consuming. Our group has been developing a real-time, cost effective immuno-optical biosensor for FVL diagnosis. For the sensor development, pure FVL, which is not currently available, is needed. Here, we have attempted FVL purification from FVL patient's plasma. Since plasma contains many proteins and some proteins are structurally homologous to FV, the purification must be done by a very specific method, such as immuno-affinity chromatography. However, an antibody that does not react with FV is not currently available. Because the mutation is in the heavy chain and the amino acid sequence of the light chain of FVL is identical to that of FV, antibodies generated against the light chain of FV were tested for purifying FVL. Plasma was obtained from a homozygous FVL patient. First, the plasma was pretreated by barium citrate and polyethylene glycol 6000, to remove the vitamin K-dependent proteins, alpha globulins, and other smaller than 6 kDa molecular weight proteins. The yield in the process was 54%. Immuno-affinity purification of FVL from patient plasma was then performed using an anti-FV light chain antibody immobilized CNBr-Sepharose, and the purification yield was 25%. In summary, the antibody against the light chain of FV was able to purify the single point mutated form of FV (FVL) from plasma with an overall yield of 14%. The same principle can probably be used for purification of the other single point mutated proteins.
机译:因子V(FV)是血浆中的凝结剂。 FV分子由重链和轻链组成,因子V莱顿(FVL)在重链中的单个氨基酸处突变为FV。 FVL患者的身体处于危险的高凝状态。当前的FVL诊断是通过DNA分析完成的,这既昂贵又费时。我们小组一直在开发用于FVL诊断的实时,经济高效的免疫光学生物传感器。为了开发传感器,需要目前尚不可用的纯FVL。在这里,我们尝试了从FVL患者血浆中纯化FVL。由于血浆包含许多蛋白质,并且某些蛋白质在结构上与FV同源,因此必须通过非常特殊的方法(例如免疫亲和色谱法)进行纯化。但是,目前尚不存在不与FV反应的抗体。因为突变在重链中,并且FVL轻链的氨基酸序列与FV相同,所以测试了针对FV轻链产生的抗体以纯化FVL。从纯合子FVL患者获得血浆。首先,血浆用柠檬酸钡和聚乙二醇6000预处理,以去除维生素K依赖性蛋白,α球蛋白和其他分子量小于6 kDa的蛋白。该方法的产率为54%。然后使用抗FV轻链抗体固定的CNBr-Sepharose从患者血浆中进行免疫亲和纯化FVL,纯化产率为25%。总之,针对FV轻链的抗体能够从血浆中纯化FV的单点突变形式(FVL),总产率为14%。相同的原理可能可以用于其他单点突变蛋白的纯化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号